Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe

Cheng Zhang, Yiping Chen, Xinmiao Liang, Guanhua Zhang, Hong Ma, Leng Nie, Yu WangSensors 2017 · OpenReview

TL;DR

This paper presents a novel, low-cost, and sensitive fluorescent detection method for the M204I mutation in Hepatitis B Virus (HBV) DNA using quantum dots (QDs). This QD-based approach offers a simpler and more accessible alternative to traditional sequencing for identifying drug-resistant HBV strains in patient serum.

What Problem Does This Paper Address?

Chronic Hepatitis B (CHB) affects millions worldwide, and a significant challenge in its treatment is the emergence of drug-resistant HBV strains. Antiviral therapies, while effective, can exert selective pressure, leading to mutations in the HBV genome, such as the M204I mutation in the HBV polymerase gene. This mutation is a key indicator of resistance to nucleos(t)ide analog (NA) treatments, leading to treatment failure and increased risk of adverse outcomes. Current methods for detecting these mutations, like direct sequencing, can be complex, expensive, and sometimes lack the sensitivity needed for early detection, especially in clinical settings with limited resources. The authors aim to develop a more accessible, sensitive, and cost-effective method for identifying these critical mutations.

Methods

The core of this work is a quantum dot (QD)-mediated fluorescent assay. The method involves:

  1. DNA Extraction and Amplification: HBV DNA is extracted from patient serum using magnetic nanobeads. A specific PCR amplification step is then performed using primers designed to selectively amplify the M204I mutant gene. This selective amplification is crucial for distinguishing between wild-type and mutant sequences.
  2. Probe Design and Immobilization: A capture probe (amino-fixed) is immobilized onto an amino-modified glass slide. A reporter probe, labeled with biotin, is designed to hybridize to the amplified HBV DNA.
  3. Hybridization and QD Labeling: The amplified HBV DNA (containing the M204I mutation) is hybridized to the capture probe on the slide. Subsequently, biotin-labeled DNA is added to hybridize to the other side of the amplified HBV DNA. Finally, streptavidin-conjugated quantum dots (QDs) are added. Streptavidin has a high affinity for biotin, allowing the QDs to bind to the hybridized DNA complex.
  4. Fluorescence Detection: The presence of QDs, indicating the presence of the M204I mutation, is visualized and quantified using fluorescence microscopy. The fluorescence intensity is correlated with the viral load.

The novelty lies in the integration of QD fluorescence with a specific DNA hybridization assay for mutation detection, aiming for simplicity and sensitivity.

Datasets

The study utilized serum samples from 28 chronic hepatitis B patients who had received lamivudine (LAM) treatment and exhibited poor response or virological breakthrough. These samples were collected between 2009 and 2016 from Beijing Friendship Hospital. The samples were analyzed using both the developed QD-based method and direct sequencing for comparison.

Key Insights and Ideas

  • Quantum Dots as Sensitive Reporters: QDs, with their excellent optical properties (high brightness, photostability), serve as highly effective fluorescent probes for detecting subtle changes in DNA, making them ideal for mutation detection.
  • Selective PCR is Key: The design of primers for selective amplification of the mutant HBV DNA is critical for the assay's specificity, ensuring that only the target mutation is amplified and subsequently detected.
  • Simplicity and Accessibility: The QD-based method offers a simpler readout system compared to complex sequencing machines, making it potentially more accessible for clinical diagnostics, especially in resource-limited settings.
  • Correlation with Viral Load: The fluorescence intensity observed directly correlates with the HBV viral load, providing a semi-quantitative measure of the mutation's presence.

Key Results

  • The developed QD-based fluorescent method successfully detected the M204I mutation in HBV DNA from patient serum samples.
  • The limit of detection (LOD) for this method was determined to be 10³ IU/mL, which is considered sensitive for clinical applications.
  • The method showed good agreement with direct sequencing for identifying the M204I mutation in patients with poor treatment response.
  • In a comparative analysis, the QD method identified two samples as M204V mutations-positive, which were initially classified as mutation-negative by direct sequencing. Subsequent PCR analysis confirmed the M204V mutation, suggesting the QD method, combined with their DNA extraction technique, might offer higher accuracy in certain cases.

Limitations and Future Work

  • Limited Sample Size: The study was conducted on a relatively small cohort of 28 patients.
  • Quantitative Accuracy: While fluorescence intensity correlates with viral load, the method is primarily presented as a qualitative or semi-quantitative detection tool. Further optimization for precise quantification might be needed.
  • Specificity for Other Mutations: The current assay is specific for the M204I mutation. The authors suggest that future research should focus on developing multiplex fluorescent methods using multicolor QD nanoprobes to detect multiple HBV mutations simultaneously. This would provide a more comprehensive picture of drug resistance.

Summary updated

Abstract

Quantum dots (QDs) are semiconductor nanoparticles with a diameter of less than 10 nm, which have been widely used as fluorescent probes in biochemical analysis and vivo imaging because of their excellent optical properties. Sensitive and convenient detection of hepatitis B virus (HBV) gene mutations is important in clinical diagnosis. Therefore, we developed a sensitive, low-cost and convenient QDs-mediated fluorescent method for the detection of HBV gene mutations in real serum samples from chronic hepatitis B (CHB) patients who had received lamivudine or telbivudine antiviral therapy. We also evaluated the efficiency of this method for the detection of drug-resistant mutations compared with direct sequencing. In CHB, HBV DNA from the serum samples of patients with poor response or virological breakthrough can be hybridized to probes containing the M204I mutation to visualize fluorescence under fluorescence microscopy, where fluorescence intensity is related to the virus load, in our method. At present, the limits of the method used to detect HBV genetic variations by fluorescence quantum dots is 103 IU/mL. These results show that QDs can be used as fluorescent probes to detect viral HBV DNA polymerase gene variation, and is a simple readout system without complex and expensive instruments, which provides an attractive platform for the detection of HBV M204I mutation.
BibTeX
@inproceedings{zhang2017detection,
  author = {Cheng Zhang and Yiping Chen and Xinmiao Liang and Guanhua Zhang and Hong Ma and Leng Nie and Yu Wang},
  title = {{Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe}},
  booktitle = {Sensors},
  year = {2017},
  url = {https://openreview.net/forum?id=C5w15P2vfw},
}
Figure